Aquestive Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Daniel Barber
- Full Time Employees
- 147
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 30 Technology Drive Warren NJ United States of America 07059
- IPO Date
- Jul 25, 2018
- CIK
- 0001398733
- Website
- aquestive.com
- Similar Companies
- Business
- Aquestive Therapeutics, Inc. (NASDAQ: AQST) develops and commercializes oral film-based pharmaceuticals utilizing its proprietary PharmFilm technology to deliver complex molecules as alternatives to invasive therapies; core products include Sympazan (clobazam oral soluble film) for Lennox-Gastaut syndrome seizures, Libervant (diazepam buccal soluble film) for seizure clusters, and manufacturing of licensed products such as Suboxone (buprenorphine/naloxone sublingual film) for opioid use disorder, KYNMOBI (apomorphine sublingual film) for Parkinson's disease off-periods, Azstarys for attention deficit hyperactivity disorder, Emylif, and Ondif; the pipeline features Anaphylm (epinephrine sublingual film) in late-stage development for anaphylaxis treatment pending FDA approval and AQST-108 (epinephrine topical gel) for dermatology conditions including alopecia areata, alongside the AdrenaVerse epinephrine prodrug platform. Founded in 2004 as MonoSol Rx and rebranded in 2017, the company is headquartered in Warren, New Jersey, and operates primarily in the United States with global licensing partnerships; it targets central nervous system disorders, severe allergies, and related conditions through collaborations with pharmaceutical firms like Assertio Holdings, Hypera Pharma, and Indivior, serving patients via innovative, needle-free delivery systems. Recent developments encompass a $75 million strategic funding agreement with RTW Investments in August 2025 to support Anaphylm commercialization through 2027 pending FDA approval, leadership expansion in November 2025 with Matthew Davis, M.D. as Chief Development Officer, Gary Slatko, M.D. as interim Chief Medical Officer, and Peter Boyd promoted to Chief People Officer to drive pipeline acceleration and launch readiness, FDA orphan drug exclusivity granted in December 2024 for Libervant in children ages 2-5, reaffirmation of Anaphylm NDA submission for Q1 2025 with pediatric trials underway, and positive pharmacokinetic data from October 2024 confirming consistent delivery regardless of placement.
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?
Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call Transcript
Aquestive Therapeutics Q1 Earnings Call Highlights
Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics
Aquestive Therapeutics (AQST) Reports Q1 Loss, Beats Revenue Estimates
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET
AQST FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
AQST DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action - AQST
Will Aquestive Therapeutics (AQST) Report Negative Q1 Earnings? What You Should Know
AQST EQUITY ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
AQST Deadline: AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit
Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
AQST EQUITY ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
AQST DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action – AQST
AQST 72 HOUR DEADLINE REMINDER: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026